



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Bureau for Medical Services
Office of Pharmacy Services
350 Capitol Street - Room 251

Charleston, West Virginia 25301-3706
Phone: (304) 558-1700 - Fax: (304) 558-1542

Earl Ray Tomblin
Governor

Rocco S. Fucillo
Cabinet Secretary

Pharmaceutical and Therapeutics Committee

January 30, 2013

Location: Diamond, Rooms B10 and B11

Time: 2:00 PM – 5:00 PM

Charleston, WV 25301

(304) 558-1700

MINUTES

Members Present:

Jeffrey V. Ashley, M.D.

David Avery, M.D.

Scott Brown, R.Ph.

Teresa Dunsworth, Pharm.D. (via phone)

Rodney L. Fink, D.O.

Michael Grome, PA-C

Amelia McPeak, D.O.

Harriet Nottingham, R.Ph.

Robert Stanton, Pharm.D.

Members Not Present:

Steven R. Matulis, M.D, Chairperson

DHHR/BMS Staff Present:

Peggy King, R.Ph., Pharmacy Director

Vicki Cunningham, R.Ph., DUR Coordinator

William Hopkins, Pharmacy Operations Manager

Gail Goodnight, R.Ph., Drug Rebate Program

Director

Richard D. Sorvig, Secretary

Contract Staff/Magellan Medicaid

Administration (MMA) Staff Present:

Chris Andrews, Pharm.D.

Nina Bandali, Pharm.D.

Giovannino Perri, M.D.

Other Contract Staff/State Staff Present:

Steve Small, R.Ph., MS, Director, Rational Drug
Therapy Program

Eric Sears, R.Ph., Molina Medicaid Solutions

I. Call to Order

Dr. Robert Stanton, interim vice-chair, called the meeting to order at 2:07PM. Ms. Peggy King asked if there were any objections to Dr. Dunsworth calling into the meeting due to inclement weather. There were no objections. Ms. King also stated that because Jim Bartsch, vice-chair, had resigned from the Committee and Dr. Matulis, chair, was not able to attend the meeting, Dr. Stanton was appointed as interim vice-chair until the regularly scheduled elections are held as allowed under the P & T Committee by-laws.

II. Welcome and Introductions

All parties seated at the table introduced themselves.

III. Housekeeping Items/Updates

A. Comments from BMS

Ms. King stated that the P&T Committee members should update their contact information if anything has changed.

B. Approval of the October 24, 2012 Minutes

Approval of October 24, 2012 P&T meeting minutes was tabled until after the executive session.

C. PDL Compliance/Generic Percent Report Updates

Dr. Chris Andrews reviewed the Preferred Drug List (PDL) Compliance Report; overall compliance for Q3 2012 was 96%. Dr. Andrews reported that the overall generic utilization rate for Q3 2012 was 74.5%.

IV. Public Comments

Ms. King explained the public comment process.

Linda Posta, Astellas, spoke in favor of Myrbetriq.

Dr. Gregg Morrow, Genzyme, spoke in favor of Aubagio.

Kent Hunter, Pfizer, spoke in favor of Xeljanz.

Dr. Melvin Saludes, pulmonologist representing Forest, spoke in favor of Tudorza.

V. Executive session

The motion was made and seconded to adjourn to executive session for confidential pricing discussion. A vote was taken and the motion was approved at 2:25PM. The meeting resumed at 2:51PM.

VI. Old Business

There was no old business.

VII. New Business

A. Classes to Retire

Dr. Andrews recommended that the Cough & Cold PDL class be removed from the PDL and instead be managed by a maximum allowed cost (MAC) process. A motion was made to retire the Cough & Cold class from the PDL. The motion was seconded, vote was taken and the motion passed.

B. New Generics

Dr. Andrews explained to the P&T Committee that the following generics are new to the market and stasured as nonpreferred:

- trospium ER (generic for Sanctura XR)
- tiagabine (generic for Gabitril)
- diclofenac/misoprostol (generic for Arthrotec)
- sildenafil (generic for Revatio)
- griseofulvin (generic for Grifulvin)
- fenofibrate nanocrystallized (generic for Tricor)
- candesartan/HCTZ (generic for Atacand Hct)
- oxymorphone ER (generic for Opana ER)
- betamethasone valerate foam (generic for Luxiq foam)
- rizatriptan/rizatriptan ODT (generic for Maxalt/Maxalt MLT)
- lamotrigine ER (generic for Lamictal XR)
- desloratadine ODT (generic for Clarinex ODT)
- pioglitazone/glimepiride (generic for Duetact)
- methylphenidate CD (generic for Metadate CD)

In addition, phenytoin chewable tablets (generic for Dilantin infatabs) and montelukast granules (generic for Singulair granules) are new to the market and recommended as preferred.

There was a question regarding access to brand name Dilantin. Ms. King explained that if the physician requested that brand was medically necessary then the pharmacist can enter a code and the brand name product would pay. In addition, Dr. Andrews confirmed that these are AB-rated generics.

The motion to approve the new generics as presented was made and seconded. A vote was taken and the motion was approved.

C. New Drug Reviews

The Committee requested that the recommendations of the new drug reviews be handled in a single motion.

1. Forfivo XL

MMA recommended that Forfivo XL be made a non-preferred drug in the Antidepressants, Other category.

ANTIDEPRESSANTS, OTHER	
MAOIs^{AP}	
PARNATE (tranylcypromine) phenelzine	MARPLAN (isocarboxazid) NARDIL (phenelzine) tranylcypromine
SNRIS^{AP}	
venlafaxine ER capsules	EFFEXOR (venlafaxine) EFFEXOR XR (venlafaxine) PRISTIQ (desvenlafaxine)

	venlafaxine IR VENLAFAXINE ER TABLETS (venlafaxine)
SECOND GENERATION NON-SSRI, OTHER^{AP}	
bupropion IR bupropion SR bupropion XL mirtazapine trazodone	APLENZIN (bupropion hbr) DESYREL (trazodone) EMSAM (selegiline) FORFIVO XL (bupropion) nefazodone OLEPTRO ER (trazodone) REMERON (mirtazapine) WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion) VIIBRYD (vilazodone hcl)
SELECTED TCAs	
imipramine hcl	imipramine pamoate TOFRANIL (imipramine hcl) TOFRANIL PM (imipramine pamoate)

2. Myrbetriq

MMA recommended that Myrbetriq be made a non-preferred drug in the Bladder Relaxant Preparations category.

BLADDER RELAXANT PREPARATIONS^{AP}	
oxybutynin IR oxybutynin ER TOVIAZ (fesoterodine) VESICARE (solifenacin)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin) DITROPAN XL (oxybutynin) ENABLEX (darifenacin) flavoxate GELNIQUE (oxybutynin) MYRBETRIQ (mirabegron) OXYTROL (oxybutynin) SANCTURA (trospium) SANCTURA XR (trospium) tolterodine trospium trospium ER ^{NR}

3. Binosto

MMA recommended that Binosto be made a non-preferred drug in the Bone Resorption Suppression and Related Agents category.

BONE RESORPTION SUPPRESSION AND RELATED AGENTS	
BISPHOSPHONATES	
alendronate	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/ calcium) ATELVIA (risedronate) BINOSTO (alendronate) BONIVA (ibandronate) DIDRONEL (etidronate) etidronate

	FOSAMAX TABLETS (alendronate) FOSAMAX PLUS D (alendronate/vitamin D) ibandronate
OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS	
MIACALCIN (calcitonin)	calcitonin EVISTA (raloxifene) FORTEO (teriparatide) FORTICAL (calcitonin)

4. Suprax chewable tablets

MMA recommended that Suprax chewable tablets be made non-preferred in the Cephalosporins and Related Antibiotics category.

CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral)^{AP}	
SINGLE INGREDIENT	
BETA LACTAMS AND BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS	
amoxicillin/clavulanate IR	amoxicillin/clavulanate ER AUGMENTIN (amoxicillin/clavulanate) AUGMENTIN XR (amoxicillin/clavulanate) MOXATAG (amoxicillin)
CEPHALOSPORINS	
cefaclor capsule cefadroxil capsule, tablet cefdinir cefuroxime tablet cephalexin capsule, suspension	CECLOR (cefaclor) CEDAX (ceftibuten) cefaclor ER tablet cefadroxil suspension cefditoren cefpodoxime cefprozil CEFTIN (cefuroxime) cefuroxime suspension CEFZIL (cefprozil) cephalexin tablet DURICEF (cefadroxil) KEFLEX (cephalexin) OMNICEF (cefdinir) PANIXINE (cephalexin) RANICLOR (cefaclor) SPECTRACEF (cefditoren) SUPRAX (cefixime) VANTIN (cefpodoxime)

5. Combivent Respimat

MMA recommended that Combivent Respimat continue to be preferred in the Bronchodilators & Respiratory Drugs category.

BRONCHODILATORS & RESPIRATORY DRUGS	
ANTICHOLINERGIC^{AP}	
ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium)	TUDORZA (acridinium)
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS^{AP}	
COMBIVENT CFC (albuterol/ipratropium) COMBIVENT RESPIMAT (albuterol/ipratropium)	albuterol/ipratropium DUONEB (albuterol/ipratropium)

PDE4 INHIBITOR	
	DALIRESP (roflumilast)

6. Tudorza

MMA recommended that Tudorza be made non-preferred in the Bronchodilators & Respiratory Drugs category.

BRONCHODILATORS & RESPIRATORY DRUGS	
ANTICHOLINERGIC ^{AP}	
ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium)	TUDORZA (aclidinium)
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS ^{AP}	
COMBIVENT CFC (albuterol/ipratropium) COMBIVENT RESPIMAT (albuterol/ipratropium)	albuterol/ipratropium DUONEB (albuterol/ipratropium)
PDE4 INHIBITOR	
	DALIRESP (roflumilast)

7. Xeljanz

MMA recommended that Xeljanz be made non-preferred in the Cytokine & CAM Antagonists category.

CYTOKINE & CAM ANTAGONISTS ^{CL}	
ENBREL (etanercept) HUMIRA (adalimumab)	CIMZIA (certolizumab pegol) KINERET (anakinra) ORENCIA (abatacept) SIMPONI (golimumab) STELARA (ustekinumab) XELJANZ (tofacitinib)

8. Aubagio

MMA recommended that Aubagio be made non-preferred in the Multiple Sclerosis category.

MULTIPLE SCLEROSIS AGENTS ^{CL, AP}	
INTERFERONS	
AVONEX (interferon beta-1a) AVONEX PEN (interferon beta-1a) BETASERON (interferon beta-1b) REBIF (interferon beta-1a)	EXTAVIA (interferon beta-1b)
NON-INTERFERONS	
COPAXONE (glatiramer)	AMPYRA (dalfampridine)* GILENYA (fingolimod)** AUBAGIO (teriflunomide)

9. Ultresa

MMA recommended that Ultresa be moved to non-preferred in the Pancreatic Enzymes category.

PANCREATIC ENZYMES^{AP}

CREON
PANCRELIPASE 5000
ZENPEP

PANCREAZE
PERTZYE
ULTRESA
VIOKACE

A motion was made, seconded, and approved to accept the recommendations by MMA for these new drugs.

VIII. Next Meeting

The next P&T meeting is scheduled for April 24, 2013 at 2PM-5PM in the Bureau for Medical Services' offices, Diamond Building, 350 Capitol Street, Charleston, WV.

IX. Other Business

A motion was made to accept the minutes from the October 24, 2012 P&T Committee meeting. The motion was seconded and the motion passed to accept the minutes as submitted.

X. Adjournment

The meeting was adjourned at 2:59PM.